Sarcopenia Treatment Market Outlook:
Sarcopenia Treatment Market size was valued at USD 3.5 billion in 2024 and is estimated to reach USD 8.9 billion by the end of 2037, exhibiting a CAGR of 9.8% during the forecast period, i.e., 2025-2037. In 2025, the industry size of sarcopenia treatment is assessed at USD 3.7 billion.
Better infrastructure availability for research and development has incorporated innovative strategies in sarcopenia treatment, which has boosted the market. Therapeutic innovation is likely to be the potential factor that has made the sarcopenia treatment market most aspirant towards growth. According to the report published by the World Health Organization, more than 48 million cases of sarcopenia are registered annually within the global platform. Approximately 32% of the aged population is identified to be at risk of sarcopenia, which has led to high demand for therapeutic health care.
Cost management within the sarcopenia treatment has increased due to the economic pressure and supply chain disruption. Data published by the U.S. Bureau of Labor Statistics has addressed a 5.3% annual increase in PPI in 2024. Inflation has resulted in the escalation of CPI within the healthcare sector. As per the report, the U.S. and EU have experienced a rise in CPI of 7.2% in 2024 within the sarcopenia treatment.
Sarcopenia Treatment Market Growth Drivers and Challenges:
Growth Drivers
- Government spending and insurance policies: Government initiatives to elevate the sarcopenia treatment are quite significant. The U.S. has contributed USD 2.2 billion in 2023 to enhance the infrastructure and R&D to ensure better service-providing ability and create demand for the market. The Government of Germany has also played a pivotal role in health care escalation through allocating €420 million in 2024 within an initiative of muscle-wasting prevention programs. Subsidy has also been provided for protein supplements and adequate resistance training.
- Ageing population: The global market is experiencing a growth in the aging population, which has created an elevated demand for sarcopenia treatment. According to the report published by the Statistical Office of the European Union, 22 million cases of sarcopenia is registered in 2025. The global population has been predicted to double by 2050, and more than 2.2 billion people by 2037, over the age of 60, will be fueling demand for the concerned treatment.
Key Market Dynamics for Historical Patient Growth
Growth of the ageing population within the year slab of 2010-2020 has resulted in a pivotal switch of the sarcopenia treatment. The annual growth of the patient at an average within the global platform ranged between 4.9% and 8.2% annually. The U.S., Japan, and the EU have evolved as developed markets due to their geriatric demographics. Historical growth of patients is categorized based on three critical dynamics of the sarcopenia treatment market, which include standardized care, early-mover, and emerging market latency.
The following table denotes historical patient growth in the past ten years across different countries:
|
Country |
2010 Procedures (millions) |
2020 Procedures (millions) |
CAGR (%) |
|
U.S. |
2.3 |
3.9 |
6.3% |
|
Germany |
1.9 |
2.9 |
6.6% |
|
France |
1.1 |
1.9 |
6.8% |
|
Spain |
0.9 |
1.5 |
7.4% |
|
Japan |
2.01 |
3.7 |
6.9% |
|
India |
0.7 |
1.02 |
8.6% |
|
China |
1.5 |
3.3 |
10.3% |
Revenue Potential for Sarcopenia Treatment
Opportunities possessed within the sarcopenia treatment market of sarcopenia treatment have diverse aspects. Standardization of the service through a premium pricing strategy within the U.S. is conducted. This has resulted in an elevation of Medicare sarcopenia treatment spending up to 42%. India has incorporated a cost-generic hybrid model that has resulted in more than 82% of patients in India being dependent on low-cost generics. Japan has made the screening of sarcopenia as per the mandate of MHLW from the age of 50, which has expanded the preventive care.
Revenue Impact 2014-2024
|
Region |
Strategy Implemented |
Revenue Impact (USD) |
|---|---|---|
|
India |
Regional API sourcing |
USD 202 million |
|
China |
NMPA Partnership |
USD 903 million |
|
USA |
Medicare development and insurance coverage |
USD 2.7 billion |
Challenges
- Government control of price and reimbursement issues: Governments have higher intervention in controlling the pricing strategy of the services. For instance, EU price caps are regulated based on the statutory AMNOG of Germany. This has resulted in Novartis reducing its price of the myostatin inhibitor by 22% in 2023. This has been a potential challenge for the company to secure its profitability and capital accumulation. Patients have not felt fully covered by the insurance companies in the U.S. Only 35% of the sarcopenia patients have received the benefit of insurance coverage, which has influenced the demand within the U.S.
- Affordability barrier: The high cost of the treatment has created a barrier to free access for patients with the global platform. For instance, 80% of the population within India is out of reach of the treatment due to the higher cost. The average copayment received at an average is USD 1200, which limits the accessibility for the U.S. population to avail sarcopenia treatment. Patients with low income face a major problem in bearing the cost of treatment, as low medical coverage and restricted market access restrict robust growth.
Sarcopenia Treatment Devices Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.8% |
|
Base Year Market Size (2024) |
USD 3.5 billion |
|
Forecast Year Market Size (2037) |
USD 8.9 billion |
|
Regional Scope |
|
Sarcopenia Treatment Market Segmentation:
Therapy Segment Analysis
Based on therapy, the drug therapy is predicted to possess a 44% market share and will emerge as the most promising segment for growth. The agents have helped to inhibit myostatin and restrain muscle growth, and also help to increase muscle mass that resulting in better physical functioning. Raising the aged population and an increased number of rare diseases have boosted the demand for drug therapy within the global platform.
Age Group Segment Analysis
Based on age group segment, the geriatric population is highly vulnerable to the report published by MHLW specified that more than 38% of the population within 74-85 years are having health risk of sarcopenia. Medicare expansion is ensured, for instance, U.S. geriatric treatment has led to more than 70% of the coverage for sarcopenia. This expanded the sarcopenia treatment market and ensured higher accessibility of diverse patients, and led to the growth of the concerned market. A projection to achieve more than 40% of market share in 2037 within the geriatric population segment of the market.
Our in-depth analysis of the global sarcopenia treatment market includes the following segments:
|
Segment |
Subsegment |
|
Therapy |
|
|
Age Group |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSarcopenia Treatment Market Regional Analysis:
North America Market Insights
The current market size is approximately USD 1.59 billion, which is predicted to achieve a market share of 51.2% in 2037. The FDA approvals for fast-action drugs for sarcopenia, like myostatin inhibitors and bimagrumab, among others, are the key growth driver within the concerned market. which has encouraged the sarcopenia treatment market to grow.
In the U.S. market, treatment for sarcopenia is growing steadily due to the rising awareness related to the risk of muscle loss. It is anticipated to achieve a growth of market share by 76% in 2037. As per the medical evaluation report published by the National Health Services, sarcopenia is marked as a significant health risk. Raising awareness and adequate diagnosis within a geriatric population is necessary. The government has taken the initiative to allocate more funds within the healthcare budget to develop the infrastructure of sarcopenia treatment. Specifically, a drastic shift within the biologics market share to 64% and tele-rehabilitation platform to 24% in 2037 projected. According to the sarcopenia treatment market analysis of NIH, the expectation of growth in therapy by 46% is identified in the country.
The sarcopenia market of Canada possesses a patient coverage of 2.5 times higher in Ontario as comparison to Alberta. It is expected to gain a market share of 26% by 2037 in the sarcopenia market. The Government of Canada has allocated more than USD 549 million for research and development within the healthcare market. Ontario’s Digital Health Strategy has reflected its project of growth in tele-rehab up to 23% in 2037. Key growth within the segments of sarcopenia treatment has projected escalation of market share up to 55% within biologics by 2037. Better digital infrastructure and improved research and development created a high probability of growth of the sarcopenia treatment market in Canada.
Europe Market Insights
The sarcopenia treatment market of Europe is estimated to achieve a market size of approximately USD 995.68 million in 2024 with a CAGR of 6.3%. A projection is made for market expansion and securing a market share of 36.7% in 2037 within the concerned market. According to the report presented by the WHO has addressed the aged population will reach more than 290 million by 2050. This creates a steady market demand and expansion of the market for sarcopenia treatment in Europe.
The UK sarcopenia treatment market has experienced constant growth due to the increasing number of the aged population and rising awareness of the risk of sarcopenia. The concerned market has secured a market share of 28.1%, and a projection has been made to achieve more than 44.5% market share in 2037. Specifically. The nutrition and exercise-oriented treatment market within sarcopenia treatment is projected to rise in the UK. Although the cost-effectiveness of the treatment has led to slower uptake by the NHS in the UK.
the ageing population is considerably higher in comparison to the UK, which makes it more suitable for the growth of the sarcopenia treatment market. A prediction to secure the sarcopenia treatment market share of more than 56.8% by 2037. A high possibility of advancing novel biologics is quite high in Germany. Strategies like adapting faster drugs and, strong pharmaceutical industry will be the key driving factor for the projected growth in the market of Germany within 2037. A large market of an aging workforce and expanded healthcare spending is one of the primary driving factors for the growth of the market.
Key Sarcopenia Treatment Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The global market of the sarcopenia treatment possesses a dominant share of nutrition companies and pharmaceutical giants. Research and development within the sarcopenia treatment is the most key aspects that have elevated the company performance, like Nestle, Abbott, and many more. Market expansion strategies such as acquisition and collaboration have resulted in escalated business performance within the global platform. Large pharmaceutical companies have collaborated with biotech firms to leverage the treatment procedure. Apart from that, personalization and digital integration focused on for higher patient engagement.
Here is a list of key players operating in the global sarcopenia treatment market:
|
Company Name |
Country of Origin |
Market Share (2024) |
|
Nestlé Health Science |
Switzerland |
24.2% |
|
Abbott Laboratories |
U.S. |
21.3% |
|
Pfizer Inc. |
U.S. |
17.2% |
|
Sanofi S.A. |
France |
13.9% |
|
GlaxoSmithKline plc |
UK |
4.4% |
|
Bayer AG |
Germany |
xx% |
|
Novartis AG |
Switzerland |
xx% |
|
Eli Lilly and Company |
U.S. |
xx% |
|
Amgen Inc. |
U.S. |
xx% |
|
Fresenius Kabi |
Germany |
xx% |
|
Zydus Cadila |
India |
xx% |
|
Cadila Healthcare Ltd |
India |
xx% |
|
Blackmores Ltd |
Australia |
xx% |
|
Usana Health Sciences |
U.S. |
xx% |
|
Amway Corporation |
U.S. |
xx% |
Below are the areas covered for each company under the top global manufacturers:
Recent Developments
- In December 2024, Phase 2a trials for MYMD-1 is presented by TNF Pharma. The trial outcome has resulted in a reduction in the inflammatory biomarkers that can be achieved within 28 days of the care period for aged patients with sarcopenia.
- In June 2024, Nestlé Health Science launched its new product of Boost Muscle Health, as the developed version with a changed composition. Hydroxy β-Methylbutyrate, and high protein content of 20g in each serving, will be a clinical backing to reduce muscle loss and wasting.
Author Credits: Radhika Pawar
- Report ID: 7775
- Published Date: Jun 18, 2025
- Report Format: PDF, PPT
